Confirming the association with a more aggressive clinical phenotype, RIG‐I was expressed at higher levels in cancers that recurred after (or progressed under) adjuvant, platinum‐based chemotherapy (p = 0.029, Fig. 2c). This evidence concerns the gene RIGI and cancer.